Performance of CO ‐ RADS in the diagnosis of COVID ‐19 in hemodialysis patients
Therapeutic Apheresis and Dialysis · 2025
DOI: 10.1111/1744-9987.14215 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Apheresis and Dialysis, 2025. Verfasst von Pervin Ozkan Kurtgoz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, University of Health Sciences, Konya City Hospital, Konya, Turkey. Hauptthemen laut MEDLINE: COVID-19, Renal Dialysis, Tomography, X-Ray Computed. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Introduction
Different data systems have been used to reach a common decision in the interpretation of chest computed tomography (CT) scans for the detection of COVID‐19 infection. The aim of our study was to determine the usefulness of the COVID‐19 Reporting and Data System (CO‐RADS) for COVID‐19 in patients undergoing hemodialysis.
Methods
We included 90 hemodialysis patients who underwent chest CT and had samples available for real‐time reverse transcription‐polymerase chain reaction (RT‐PCR). The files of the patients were retrospectively reviewed and the data were recorded. Image interpretation and CO‐RADS staging were performed retrospectively by two radiologists experienced in COVID‐19 patients, blinded to the RT‐PCR results. The RT‐PCR results were then compared with the CO‐RADS stages obtained. The success of CO‐RADS in diagnosing COVID‐19 was evaluated according to its prediction of a positive RT‐PCR result. At the same time, the relationship between CO‐RADS stages and prognosis was also evaluated.
Results
Patients were divided into two groups according to the RT‐PCR results, of which 38 (42.2%) had positive results. Validity tests of CO‐RADS were performed according to the RT‐PCR test. While 71.1% of patients with CO‐RADS ≥4 were RT‐PCR (+), 13.2% of patients with CO‐RADS ≤2 were RT‐PCR (+) ( p < 0.001). CO‐RADS ≥4 detected COVID‐19 with 71.1% sensitivity and 51.9% specificity. ROC analysis confirmed the diagnostic performance of CO‐RADS for predicting RT‐PCR positivity with AUC = 0.73 (95% CI: 0.63–0.84). The relationship between CO‐RADS stages and mortality was not significant ( p = 0.21).
Conclusion
CO‐RADS is moderately sensitive and poorly specific for the diagnosis of COVID‐19 in hemodialysis patients. In these patients, CO‐RADS would be more useful to exclude other infections than to diagnose COVID‐19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Department of Internal Medicine, University of Health Sciences, Konya City Hospital, Konya, Turkey.
- Department of Internal Medicine, University of Health Sciences, Konya City Hospital, Konya, Turkey.
- Department of Radiology, University of Health Sciences, Konya City Hospital, Konya, Turkey.
ORCID-Profile: Pervin Ozkan Kurtgoz, Fatih Sackan, Meral Buyukterzi, Ibrahim Guney
Zitieren
APA
Ozkan Kurtgoz, P., Sackan, F., Buyukterzi, M., & Guney, I. (2025). Performance of CO ‐ RADS in the diagnosis of COVID ‐19 in hemodialysis patients. Therapeutic Apheresis and Dialysis. https://doi.org/10.1111/1744-9987.14215
Vancouver
Ozkan Kurtgoz P, Sackan F, Buyukterzi M, Guney I. Performance of CO ‐ RADS in the diagnosis of COVID ‐19 in hemodialysis patients. Therapeutic Apheresis and Dialysis. 2025. doi:10.1111/1744-9987.14215
BibTeX
@article{OzkanKurtgoz2025,
author = {Ozkan Kurtgoz, Pervin and Sackan, Fatih and Buyukterzi, Meral and Guney, Ibrahim},
title = {Performance of CO ‐ RADS in the diagnosis of COVID ‐19 in hemodialysis patients},
journal = {Therapeutic Apheresis and Dialysis},
year = {2025},
doi = {10.1111/1744-9987.14215}
}
EUVIMED